BioPharma Credit PLC (BPCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioPharma Credit PLC (BPCR) has a cash flow conversion efficiency ratio of 0.029x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($33.76 Million) by net assets ($1.15 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can BioPharma Credit PLC fund operations to measure how many days the company can operate on defensive assets alone.
BioPharma Credit PLC - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how BioPharma Credit PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioPharma Credit PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioPharma Credit PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Pacific Union Precision Manufacturing Co. Ltd. A
SHG:688210
|
N/A |
|
180 Life Sciences Corp
NASDAQ:ATNF
|
-0.037x |
|
Guangzhou Ruoyuchen Information Tec
SHE:003010
|
0.373x |
|
Fujian Aonong Biological Technology Group Incorporation Ltd
SHG:603363
|
0.008x |
|
SHANGHAI FU. MIC.H YC-10
F:FUD
|
N/A |
|
Elco Ltd
TA:ELCO
|
-0.042x |
|
Blacksky Technology Inc
NYSE:BKSY
|
-0.029x |
|
Eerly Govt Ppty Inc
NYSE:DEA
|
0.020x |
Annual Cash Flow Conversion Efficiency for BioPharma Credit PLC (2017–2024)
The table below shows the annual cash flow conversion efficiency of BioPharma Credit PLC from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see how much is BioPharma Credit PLC worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.18 Billion | $111.91 Million | 0.095x | +3.09% |
| 2023-12-31 | $1.34 Billion | $123.18 Million | 0.092x | -33.31% |
| 2022-12-31 | $1.34 Billion | $184.28 Million | 0.138x | +94.80% |
| 2021-12-31 | $1.36 Billion | $96.44 Million | 0.071x | +67.91% |
| 2020-12-31 | $1.38 Billion | $58.07 Million | 0.042x | -55.05% |
| 2019-12-31 | $1.40 Billion | $131.52 Million | 0.094x | +92.59% |
| 2018-12-31 | $1.38 Billion | $67.14 Million | 0.049x | +94.57% |
| 2017-12-31 | $922.57 Million | $23.07 Million | 0.025x | -- |
About BioPharma Credit PLC
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. The company debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in Leeds, the United Kingdom.